Eine extra-welfaristische Evaluation der Arzneimittelregulierung

Abstract

Since 1961 access to market for innovative pharmaceuticals was increasingly regulated. The first step was a simple registration procedure, followed by federal licensing in 1978. Since 1989 the licensing was complemented by price control in form of a maximum allowable cost scheme ("Festbetragsregelung"). Since 2004 the additional benefit of new medicines is determined as a mean to guarantee acceptable "value for money" for the statutory health insurance. This thesis evaluates this aggregate of regulatory mechanisms particurlarly with regard to the quality of the supply of new medicines.